Chlamydia
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
2 programsAntigen-Specific Cell Mediated Immune Response to Chlamydia TrachomatisN/A1 trial
Chlamydia, gonorrhea, syphilis, and HIV screeningN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Allergy TherapeuticsChlamydia, gonorrhea, syphilis, and HIV screening
Human BioSciencesHome Screening
Allergy TherapeuticsAntigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
Clinical Trials (3)
Total enrollment: 2,577 patients across 3 trials
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
Start: Sep 2024Est. completion: Sep 20292,322 patients
N/ANot Yet Recruiting
Randomized Trial of Home Versus Clinic-Based STD Testing
Start: Jun 2010Est. completion: Dec 2011200 patients
N/ACompleted
NCT00970749Allergy TherapeuticsAntigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis
Start: Dec 2009Est. completion: Jun 201055 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.